This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Cooper Companies Inc (COO), based in Pleasanton, CA, is a specialty medical device company operating on a global basis. Cooper has two business segments- CooperVision (CVI) and CooperSurgical (CSI). CooperVision manufactures and sells a wide range of contact lenses. CooperVision develops manufactures and markets a broad range of single-use, two-week and monthly contact lenses, featuring advanced materials and optics. The company’s products are primarily designed for solving vision challenges like astigmatism, presbyopia and ocular dryness. CooperSurgical sells a variety of medical devices and surgical instruments that are primarily utilized by gynecologists and obstetricians. This strategic business unit has pursued a strategy of consolidation by acquiring critical treatment niches in a fragmented market.
Henry Schein (HSIC) Lags Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Henry Schein (HSIC) delivered earnings and revenue surprises of -5.71% and 1.83%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Unveiling The Cooper Companies (COO) Q1 Outlook: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of The Cooper Companies (COO) for the quarter ended January 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
The Cooper Companies (COO) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
The Cooper Companies (COO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LH vs. COO: Which Stock Is the Better Value Option?
by Zacks Equity Research
LH vs. COO: Which Stock Is the Better Value Option?
Labcorp (LH) Surpasses Q4 Earnings and Revenue Estimates (Revised)
by Zacks Equity Research
Labcorp (LH) delivered earnings and revenue surprises of 0.30% and 0.86%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Labcorp (LH) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Labcorp (LH) delivered earnings and revenue surprises of 0.30% and 0.86%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Cooper Companies (COO), Fulgent Unite to Boost Genetic Testing
by Zacks Equity Research
Cooper Companies (COO) collaborates with Fulgent Genetics to boost newborn genetic screenings. CBR by Cooper Surgical is likely to provide a variety of genetic testing options to its families.
Reasons to Retain The Cooper Companies (COO) in Your Portfolio Now
by Zacks Equity Research
The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is concerning.
Cooper Companies (COO) Q4 Earnings In Line, '23 Outlook Raised
by Zacks Equity Research
Cooper Companies' (COO) fourth-quarter fiscal 2023 revenues reflect a solid segmental performance with improved adjusted earnings amid moderating expenses.
Compared to Estimates, The Cooper Companies (COO) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for The Cooper Companies (COO) give a sense of how its business performed in the quarter ended October 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
What's in Store for Cooper Companies (COO) in Q4 Earnings?
by Zacks Equity Research
Cooper Companies' (COO) fiscal fourth-quarter results are likely to reflect segmental strength.
The Cooper Companies (COO) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for The Cooper Companies (COO), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended October 2023.
The Cooper Companies (COO) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
The Cooper Companies (COO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Reasons to Retain The Cooper Companies (COO) in Your Portfolio
by Zacks Equity Research
The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is concerning.
McKesson (MCK) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
McKesson's (MCK) second-quarter fiscal 2024 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.
Revvity (RVTY) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Revvity's (RVTY) third-quarter results are likely to reflect weak performance at the Diagnostics segment, partially offset by strong demand for Life Sciences and Diagnostics franchise.
DexCom (DXCM) to Report Q3 Earnings: Is a Beat in Store?
by Zacks Equity Research
DexCom's (DXCM) third-quarter 2023 results are likely to reflect rising volumes across all channels.
XRAY or COO: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
XRAY vs. COO: Which Stock Is the Better Value Option?
Reasons to Retain The Cooper Companies (COO) in Your Portfolio
by Zacks Equity Research
The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is concerning.
Cooper Companies (COO) Q3 Earnings In Line, '23 Outlook Raised
by Zacks Equity Research
Cooper Companies' (COO) third-quarter fiscal 2023 revenues reflect a solid segmental performance with improved adjusted earnings amid rising expenses.
The Cooper Companies (COO) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for The Cooper Companies (COO) give a sense of how its business performed in the quarter ended July 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
The Cooper Companies (COO) Q3 Earnings Match Estimates
by Zacks Equity Research
The Cooper Companies (COO) delivered earnings and revenue surprises of 0% and 3.31%, respectively, for the quarter ended July 2023. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Cooper Companies (COO) Ahead of Earnings?
by Zacks Equity Research
Cooper Companies (COO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Is a Beat Likely for Cooper Companies (COO) in Q3 Earnings?
by Zacks Equity Research
Cooper Companies' (COO) fiscal third-quarter results are likely to reflect segmental strength.
Is a Beat Likely for Patterson Companies (PDCO) in Q1 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal first-quarter results are likely to reflect an improvement at both Dental and Animal Health segments.